- Home
- CFFN vs GYRE Comparison
CFFN vs GYRE Comparison
Compare CFFN & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFFN
- GYRE
- Stock Information
- Founded
- CFFN 1893
- GYRE 2002
- Country
- CFFN United States
- GYRE United States
- Employees
- CFFN N/A
- GYRE N/A
- Industry
- CFFN Savings Institutions
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CFFN Finance
- GYRE Health Care
- Exchange
- CFFN Nasdaq
- GYRE Nasdaq
- Market Cap
- CFFN 813.3M
- GYRE 897.1M
- IPO Year
- CFFN 1999
- GYRE N/A
- Fundamental
- Price
- CFFN $6.55
- GYRE $7.58
- Analyst Decision
- CFFN Hold
- GYRE Strong Buy
- Analyst Count
- CFFN 1
- GYRE 1
- Target Price
- CFFN $6.50
- GYRE $18.00
- AVG Volume (30 Days)
- CFFN 586.3K
- GYRE 92.8K
- Earning Date
- CFFN 10-22-2025
- GYRE 08-11-2025
- Dividend Yield
- CFFN 5.25%
- GYRE N/A
- EPS Growth
- CFFN N/A
- GYRE N/A
- EPS
- CFFN 0.47
- GYRE 0.02
- Revenue
- CFFN $192,483,000.00
- GYRE $102,189,000.00
- Revenue This Year
- CFFN $10.56
- GYRE $21.04
- Revenue Next Year
- CFFN $11.73
- GYRE $89.64
- P/E Ratio
- CFFN $13.78
- GYRE $445.31
- Revenue Growth
- CFFN N/A
- GYRE N/A
- 52 Week Low
- CFFN $4.90
- GYRE $6.11
- 52 Week High
- CFFN $7.20
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- CFFN 67.38
- GYRE 47.71
- Support Level
- CFFN $6.34
- GYRE $7.02
- Resistance Level
- CFFN $6.53
- GYRE $8.12
- Average True Range (ATR)
- CFFN 0.12
- GYRE 0.52
- MACD
- CFFN 0.03
- GYRE -0.01
- Stochastic Oscillator
- CFFN 100.00
- GYRE 40.58
About CFFN Capitol Federal Financial Inc.
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank, Capitol Federal Savings Bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It primarily serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.